Quarterly report pursuant to Section 13 or 15(d)

Acquisition of Patents and Intangibles (Tables)

v3.21.4
Acquisition of Patents and Intangibles (Tables)
6 Months Ended
Nov. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Summary of net purchase price and allocation to the acquired assets

(in thousands)

    

November 30, 2021

    

May 31, 2021

Leronlimab (PRO 140) patent

$

3,500

$

3,500

ProstaGene, LLC intangible asset acquisition, net of impairment

 

2,926

2,926

Website development costs

 

20

 

20

Gross carrying value

6,446

6,446

Accumulated amortization, net of impairment

 

(5,293)

 

(4,793)

Total amortizable intangible assets, net

$

1,153

$

1,653

Schedule of estimated future amortization expense

Fiscal Year (in thousands)

    

Amount

2022 (6 months remaining)

$

221

2023

217

2024

85

2025

85

Thereafter

545

Total

$

1,153